NeuroCog Trials licenses a full spectrum of cognitive batteries dedicated to facilitating clinical research.
A six-test battery currently being used in trials of compounds for medical patients, the BAC was approved by the FDA as a measure of cognition in clinical trials of Restless Leg Syndrome (RLS). One of the tests (symbol coding) is a part of the final core MATRICS battery, and another (Tower of London) is a component of the supplemental MATRICS battery. There are two variations of the BAC:
- The Brief Assessment of Cognition in Schizophrenia (BACS)
The BAC modified for schizophrenia trials, this battery has been used in over 20 multi-site clinical trials of cognitive enhancement. A computerized version of the test has been developed and is available for tablet-based administration on iTunes.
- Brief Assessment of Cognition in Affective Disorders (BAC-A)
This instrument is currently being used in multi-site clinical trials assessing cognitive treatment change in patients with bipolar disorder and depression. It includes the six tests from the BAC, plus tests of affective interference and emotional disinhibition.
The BAC and its modifications can also be used to detect improvements and declines in neurocognitive performance in a wide range of medical conditions beyond traditional CNS disorders.
The SCoRS is one of two interview-based assessments considered as possible co-primary measures of functional capacity by an FDA-NIMH Panel. It is currently being used in international phase 3 registration trials assessing cognitive treatment change in schizophrenia.
The VRFCAT is a computer based virtual reality measure of functional capacity designed for use in cognitively impaired populations. The development and ongoing validation of the instrument is funded by an NIH SBIR Phase 2 grant.
UCSD Performance-based Skills Assessment (UPSA)
The UPSA is a role-play assessment of functional capacity designed for use as a co-primary measure. There are several versions available for use.